Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2008
11/27/2008WO2008057253A3 Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
11/27/2008WO2008050140A3 Compounds for treatment of parasitic infection
11/27/2008WO2008046087A3 Spiro compounds and their uses as therapeutic agents
11/27/2008WO2008046072A3 Chemical inducers of neurogenesis
11/27/2008WO2008045294A3 Boosting immunity
11/27/2008WO2008042399A3 Method for treatment of macular degeneration
11/27/2008WO2008039566A3 Drugs and uses
11/27/2008WO2008039472A3 Stabilizing compositions for antibiotics and methods of use
11/27/2008WO2008036168A3 New small molecule inhibitors of mdm2 and the uses thereof
11/27/2008WO2008035316A3 Phosphodiesterase inhibitors
11/27/2008WO2008033956A3 Macrocyclic lactone compounds and methods for their use
11/27/2008WO2008032153A3 Calreticulin for its use as a medication for the treatment of cancer in a mammal
11/27/2008WO2008031771A3 3-azabicyclo [4. 1. 0] heptane derivatives for the treatment of depression
11/27/2008WO2008031016A3 Heterocyclic ligands for integrin imaging and therapy
11/27/2008WO2008030795A3 Compositions and methods for inhibition of tyrosine kinases
11/27/2008WO2008027340A3 Topical ophthalmic formulations
11/27/2008WO2008024438A3 2-phenoxy pyrimidinone analogues
11/27/2008WO2008024303A3 Compounds for treating proliferative disorders
11/27/2008WO2008021932A3 Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia
11/27/2008WO2008021193A3 Guanosine rich oligonucleotides and methods of inducing apoptosis in tumor cells
11/27/2008WO2008014404A3 Receptor-mediated delivery : compositions and methods
11/27/2008WO2008014266A3 Heme oxygenase inhibitors and methods of therapeutic use
11/27/2008WO2008014219A3 Thiozolidinedione derivatives as p13 kinase inhibitors
11/27/2008WO2008013997A3 Fluorescent substrates for monoamine transporters as optical false neurotransmitters
11/27/2008WO2008013963A3 Fatty acid amide hydrolase inhibitors
11/27/2008WO2008013866A3 Methods for treating acute acoustic trauma
11/27/2008WO2008011561A3 End-modified poly(beta-amino esters) and uses thereof
11/27/2008WO2008011284A3 Methods and compositions for repression of occludin
11/27/2008WO2008011176A3 Myosin light chain kinase inhibitor compounds, compositions and related methods of use
11/27/2008WO2008008373A3 Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
11/27/2008WO2007147007A3 Methods and immune modulatory nucleic acid compositions for preventing and treating disease
11/27/2008WO2007146712A3 Therapy using cytokine inhibitors
11/27/2008WO2007143468A3 Preparation and utility of substituted imidazopyridine compounds with hypnotic effects
11/27/2008WO2007143158A3 Sustained release pharmaceutical formulation comprising phenylephrine
11/27/2008WO2007140184A3 Deoxynojirimycin and d-arabinitol analogs and methods of using
11/27/2008WO2007133706A3 Antibiotic-bound poly (caprolactone) polymer
11/27/2008WO2007131253A3 Use of combination preparations comprising antifungal agents
11/27/2008WO2007127791A3 New pharmacological method for treatment of neuropathic pain
11/27/2008WO2007127366A3 Kinase inhibitors and methods of use thereof
11/27/2008WO2007127165A3 A gene therapy construct that induces selective apoptosis in cells with mutant ras and mutant p53, and methods of use for treating cancer
11/27/2008WO2007126959A3 Methods and compositions for inducing an immune response to hiv and models for testing
11/27/2008WO2007124114A3 Stereoselective reduction of a morphinone
11/27/2008WO2007121949A8 Transdermal delivery system comprising sufentanil and its analogues
11/27/2008WO2007120555A3 Assessment of heart failure risk using genetic assessment of g-protein beta-3 subunit polymorphism
11/27/2008WO2007117431A3 Use of rasagiline for the treatment of restless legs syndrome
11/27/2008WO2007114925A3 Two pore channels as a therapeutic target to protect against myocardial ischemia and as an adjuvant in cardiac surgery
11/27/2008WO2007112098A3 Uses of diphenyl/diphenylamine carboxylic acids
11/27/2008WO2007106852A3 Substituted fused[1,2]imidazo[4,5-c] ring compounds and methods
11/27/2008WO2007106508A3 Use of tetrahydropyridines in the treatment of central nervous system disorders
11/27/2008WO2007103683A3 Compounds for inhibiting beta-amyloid production
11/27/2008WO2007103233A3 Processes for synthesizing 7-alkynyl-4-aminoquinazolines and a related intermediate
11/27/2008WO2007101232A3 Inhibition of jak2 as a treatment of pulmonary arterial hypertension
11/27/2008WO2007101002A3 A novel non-selective cation channel in neuronal cells and methods for treating brain swelling
11/27/2008WO2007100917A3 Antimicrobials and related methods
11/27/2008WO2007100763A3 Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
11/27/2008WO2007098326A3 Method for screening hiv drug sensitivity
11/27/2008WO2007098090A3 Treatment of hyperproliferative diseases with n-oxides of estrogen receptor modulators
11/27/2008WO2007098086A3 Hydroxypiperidine derivatives and uses thereof
11/27/2008WO2007095523A3 Stable dosage formulations of imidazolylalkyl-pyridines
11/27/2008WO2007095387A3 Compositions and methods for inhibiting gene silencing by rna interference
11/27/2008WO2007087029A3 Use of low-dose ladostigil for neuroprotection
11/27/2008WO2007079338A3 Sterilized peritoneal dialysis solutions containing heparin
11/27/2008WO2007079051A3 Application methods to rapidly alter disease and injury states using molecular transport of b6
11/27/2008WO2007075963A3 Systems and methods for the delivery of corticosteroids
11/27/2008WO2007070228A3 Intraosseous dental anesthesia
11/27/2008WO2006034190A3 Purine derivatives and methods of use thereof
11/27/2008WO2005089504A3 Methods for the treatment of synucleinopathies
11/27/2008WO2005025498A3 Substituted acetanilides and benzamides for the treatment of asthma and pulmonary inflammation
11/27/2008WO2004103267A3 Methods to administer epothilone d
11/27/2008US20080293825 Hydroalcoholic antimicrobial composition with skin health benefits
11/27/2008US20080293823 Methods and Compositions For Treating Sleep-Related Breathing Disorders
11/27/2008US20080293822 Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
11/27/2008US20080293821 Cooling compositions
11/27/2008US20080293820 Methods for improving physical function in fibromyalgia
11/27/2008US20080293819 N-(1-cyanocyclopropyl)-4,4-difluoro-2(S)-[2,2,2-trifluoro-1(S)-(4-fluorophenyl)ethylamino)octamide; rheumatoid arthritis, multiple sclerosis, myasthenia gravis, psoriasis, pemphigus vulgaris, Graves' disease, myasthenia gravis, lupus, asthma, pain, atherosclerosis; cathepsins B, K, L, F, and S inhibitors
11/27/2008US20080293818 Regulator of Physiological Function of Ghrelin and Use Thereof
11/27/2008US20080293817 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
11/27/2008US20080293816 Use of 2,5-Dihydroxybenzenesulphonic Acid in the Production of Medicaments for the Treatment of Angiodependent Diseases Such as Cancer and Psoriasis
11/27/2008US20080293815 Hca for improved hdl serum lipids profile
11/27/2008US20080293814 Concentrate esmolol
11/27/2008US20080293813 Compositions and Methods
11/27/2008US20080293812 Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
11/27/2008US20080293811 External preparation for the the skin
11/27/2008US20080293810 Multi-dose concentrate esmolol with benzyl alcohol
11/27/2008US20080293808 Non-Steroidal Androgen Receptor Modulators, Preparation Process, Pharmaceutical Composition and Use Thereof
11/27/2008US20080293807 Skin Cosmetic and Wrinkle-Reducing Agent
11/27/2008US20080293806 Odor Reduction Compositions
11/27/2008US20080293804 Pharmaceutical Nasal Spray Formulation of Acetaminophen (paracetamol)
11/27/2008US20080293803 Melatonin daily dosage units
11/27/2008US20080293802 Chemical Compounds
11/27/2008US20080293801 Solid Amorphous Dispersions of An Mtp Inhibitor For Treatment of Obesity
11/27/2008US20080293800 Cytotoxic Compounds and Conjugates
11/27/2008US20080293799 Liver Function Ameliorant
11/27/2008US20080293797 Central nervous system disorders; respiratory system disorders; sexual or reproductive disorders; eating disorders; antidiabetic agents; cardiovascular disorders; anticancer agents
11/27/2008US20080293796 Parenteral and oral formulations of benzimidazoles
11/27/2008US20080293795 Combination therapy with parp inhibitors
11/27/2008US20080293794 Diaryltriazolmethylamine derivatives, preparation and therapeutic use thereof
11/27/2008US20080293792 (R)-2-(9-(1H-imidazol-1-yl)nonyl)-2,5,7,8-tetramethylchroman-6-ol, capable of inhibiting tocopherol-omega-hydroxylase, responsible for the metabolism of tocopherol and tocotrienol compounds of vitamin E, and thus increase the amount and prolong the bioavailability of these compounds in plasma and tissue
11/27/2008US20080293791 Valsartan salts
11/27/2008US20080293790 Substituted aryl oximes
1 ... 2975 2976 2977 2978 2979 2980 2981 2982 2983 2984 2985 2986 2987 2988 2989 2990 2991 2992 2993 2994 2995 ... 7860